Dexamethasone palmitate-loaded sHDL nanodiscs: Enhanced efficacy and safety in allergic conjunctivitis.
10.1016/j.jpha.2025.101276
- Author:
Jiawei LI
1
;
Pengyue LIU
1
;
Yue ZHANG
1
;
Fan YANG
1
Author Information
1. Department of Dermatology, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
- Publication Type:Journal Article
- Keywords:
Allergic conjunctivitis;
Dexamethasone palmitate;
Eye drops;
Nanodisc;
Th2 cells;
sHDL
- From:
Journal of Pharmaceutical Analysis
2025;15(11):101276-101276
- CountryChina
- Language:English
-
Abstract:
Allergic conjunctivitis is a common ocular surface condition. Although corticosteroids are potent anti-inflammatory agents for its management, their use is often restricted by potential side effects. Conventional eye drops face challenges such as short retention time and poor corneal permeability, resulting in low drug bioavailability. To overcome these limitations, we developed a preservative-free synthetic high-density lipoprotein (sHDL) nanodisc eye drop containing dexamethasone palmitate. This novel formulation enhances drug stability and extends retention time on the ocular surface. In a mouse model of ovalbumin (OVA)-induced allergic conjunctivitis, the nanodisc eye drop significantly alleviated symptoms while reducing corticosteroid concentration, demonstrating excellent safety and biocompatibility. This innovative approach shows great promise for the treatment of allergic conjunctivitis and may lay the groundwork for new therapeutic strategies in anterior ocular disease management.
